

THIS IS PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



MONO PHARMACARE LIMITED



(Please scan this QR code to view the Prospectus)

Our company was originally formed as a partnership firm in the name and style of "M/s. Mono Chemist" through partnership deed dated May 06, 1994. Further, the partnership firm was then converted into Public Limited company under part I (Chapter XXI) of the Companies Act, 2013 in the name and style of Mono Pharmcare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad. The corporate identification number of our Company is U24304GJ2022PLC136193. For details of incorporation, change of name and registered office of our Company, please refer to chapter titled "General Information" and "History and Certain Corporate Matters" beginning on page 51 and 125 respectively of the Prospectus.

Registered office: 1A, Krinkal Apartment Opp. Mahalaxmi Temple, Paldi Ahmedabad -380007, Gujarat.
Tel: +91-99780 41356; E-mail: cs@monopharmacare.com; Website: www.monopharmacare.com; Contact Person: Krupal Thakkar, Company Secretary and Compliance Officer
Corporate Identification Number: U24304GJ2022PLC136193

OUR PROMOTERS: PANILAM LAKHATARIYA AND SUPAL LAKHATARIYA

THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE ("NSE EMERGE")

Our Company has filed the Prospectus dated September 01, 2023, with the Registrar of Companies, Ahmedabad, Gujarat. The Equity Shares are proposed to be listed on the Emerge Platform of National Stock Exchange of India Limited ("NSE EMERGE") and the trading is expected to commence on September 07, 2023.

NOTICE TO INVESTORS

Our company had received a notice on September 04, 2023, from the Registrar of Companies, Gujarat, Dadra & Nagar Haveli, dated August 25, 2023, with reference No. ROC/TS/Mono Pharmcare/136193/2023/2369. The notice pertains to an inspection under section 206(5) of the Companies Act, 2013. In this notice, the ROC had directed the company to provide the original documents that were submitted during the application for name availability at the time of incorporation of the Company. Additionally, ROC had instructed to submit the document of Prospectus along with all enclosures within 10 days from the date of receiving the letter. The company is currently in the process of fulfilling these requirements, and it shall be completed in due course.

BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF 53,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF MONO PHARMACARE LIMITED ("COMPANY") FOR CASH AT A PRICE OF ₹ 28 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ 18 PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹ 1,484.00 LAKHS OF WHICH UP TO 2,76,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH FOR CASH AT A PRICE OF ₹ 28 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF 18 PER EQUITY SHARE AGGREGATING TO ₹ 77.28 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"), THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 50,24,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AT A PRICE OF ₹ 28 PER EQUITY SHARE AGGREGATING TO ₹ 1,406.72 IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 30.00% AND 28.43% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE PRICE: ₹ 28 PER EQUITY SHARE OF FACE VALUE OF ₹ 10 EACH THE ISSUE PRICE IS 2.8 TIMES OF THE FACE VALUE OF EQUITY SHARES

RISKS TO INVESTORS

RISK FACTORS ASSOCIATED WITH OUR COMPANY

a. The average cost of acquisition of shares of our promoters is as follows

Sr. No.	Name of Promoters	No. of Equity Shares acquired	Average Cost of acquisition Price (in ₹ per equity share)
1.	Panilam Lakhataria	80,26,761	10.73
2.	Supal Lakhataria	19,93,458	9.47

b. Weighted Average Cost of Acquisition for all Equity Shares transacted in one year, eighteen months and three years preceding the date of the Red Herring Prospectus by all the shareholders:

Period	Weighted Average Cost of Acquisition (in ₹)*	Upper end of the Price band (₹ 28) is 'X' times the Weighted Average Cost of Acquisition	Range of acquisition price: Lowest Price - Highest Price (in ₹)
Last 1 year	10.38	2.70	0-12
Last 18 months	10.38	2.70	0-12
Last 3 years	10.38	2.70	0-12

*As certified by our Statutory and Peer review Auditors M/s Kumbhat & Co., by way of their certificate dated August 22, 2023.

c. The weighted average cost of acquisition compared to floor price and cap price.

PAST TRANSACTIONS	Weighted average cost of acquisition (₹)	Floor Price ₹ 26	Cap Price ₹ 28
WACA of Primary Issue (except for bonus issue)	10.40	2.5	2.69
WACA for Secondary sale/ acquisitions not exceeding 5% of the pre issue capital	N.A	N.A	N.A

BRLM associated with the Issue has handled 8 public issues in the past three financial years. Below are the details:

Particulars	Number of issue/Offer handled	Issue closed below the issue price on listing date
Main Board	4	-
SME	4	1

d. The Price/Earnings ratio based on diluted EPS for Fiscal 2023 for our Company at the upper end of the Price Band is 14.07 times.

e. Weighted Average Return on Net Worth for fiscals 2023, 2022 and 2021 is 7.67%.

f. We rely on third parties for manufacturing products of our Company.

g. In past, we have undertaken and may continue to undertake strategic investments, acquisitions and mergers in the future, which may be difficult to integrate and manage. Our future success depends on our ability to achieve and manage growth, whether through internal growth or strategic acquisitions.

BID/ISSUE PERIOD

BID/ISSUE OPENED ON MONDAY, AUGUST 28, 2023 BID/ISSUE CLOSED ON WEDNESDAY, AUGUST 30, 2023

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations wherein not more than 10.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"). Further, 5.00% of the QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 45.00% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 45.00% of the Net Issue shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All Bidders are required to participate in the Issue by mandatorily utilising the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self-Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Issue Procedure" on page 225 of the Prospectus. The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of the Issue, the Designated Stock Exchange will be the National Stock Exchange of India Limited. The trading is proposed to be commenced on or about September 07, 2023.*

*Subject to the receipt of listing and trading approval from NSE Emerge Platform.

DETAILS OF APPLICATIONS RECEIVED:

Sr. No.	Category	Number of Applications Received	Number of Shares Bid for	Equity shares reserved as per Prospectus	No. of times subscribed	Amount of total bids (₹)
1	Market Maker	1	2,76,000	2,76,000	1.00	77,28,000
2	Retail Individual Bidders	10,999	4,39,96,000	22,64,000	18.92	1,23,11,96,000
3	Non-Institutional Bidders	926	1,81,60,000	22,60,000	7.91	50,79,44,000
4	Qualified Institutional Bidders	3	54,00,000	5,00,000	10.80	15,12,00,000
	Total	11,929	6,78,32,000	53,00,000		1,89,80,68,000

Final Demand:

A Summary of the final demand as per NSE as on Bid/Issue closing date at different Bid Price is as under:

Sr. No.	Bid Price	No. of Bids	Shares Applied	Application Amount
1	26	213	9,16,000	2,38,16,000
2	27	92	4,04,000	1,09,08,000
3	28	8,211	5,43,52,000	1,52,18,56,000
4	9,99,999	8,671	3,46,84,000	97,11,52,000
	Total	17,187	9,03,56,000	2,52,77,32,000

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange-NSE on September 04, 2023

Market Maker's Category:

The Registrar informed that in this category 1 valid application for 2,76,000 Shares were received against 2,76,000 Equity Shares reserved for this category resulting in subscription of 1.00 time.

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ration of allottees to applicants	Total No. of shares allocated /allotted
2,76,000	1	100.00	2,76,000	100.00	2,76,000	1 1	2,76,000
Grand Total	1	100.00	2,76,000	100.00	2,76,000	1 1	2,76,000

ii. Retail Individual and Non-Institutional Investors

The Registrar informed that in Retail & Non-Retail category, overall 11,607 valid applications for 1,18,14,000 Equity Shares were received.

Retail Individual Investors have been offered 45.06% of net issue of 50,24,000 shares i.e. 22,64,000 shares (after rounding off) and Non Retail category has been offered 44.98% of net issue of 50,24,000 shares i.e. 22,60,000

• Retail Individual Investors Category:

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ration of allottees to applicants	Total No. of shares allocated /allotted
4000	10,708	100.00	4,28,32,000	100.00	22,64,000	37 700	22,64,000
Grand Total	10,708	100.00	4,28,32,000	100.00	22,64,000		22,64,000

• Non Institutional Investors category

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ration of allottees to applicants	Total No. of shares allocated /allotted
8000	536	59.62	4288000	23.99	542360	17 67	544000
12000	80	8.89	960000	5.37	121424	3 8	120000
16000	95	10.56	1520000	8.5	192254	48 95	192000
20000	48	5.33	960000	5.37	121424	5 8	120000
24000	18	2	432000	2.41	54641	7 9	56000
28000	14	1.55	392000	2.19	49581	6 7	48000
32000	15	1.66	480000	2.68	60712	1 1	60000
36000	15	1.66	540000	3.02	68301	1 1	60000
36000						2 15	8000
40000	16	1.77	640000	3.58	80949	1 1	64000
40000						1 4	16000
44000	7	0.77	308000	1.72	38957	1 1	28000
44000						3 7	12000
48000	5	0.55	240000	1.34	30356	1 1	20000
48000						3 5	12000
56000	6	0.66	336000	1.88	42498	1 1	24000
56000						5 6	20000
60000	2	0.22	120000	0.67	15178	1 1	16000
64000	2	0.22	128000	0.71	16190	1 1	16000
68000	2	0.22	136000	0.76	17202	1 1	16000
72000	3	0.33	216000	1.2	27320	1 1	24000
72000						1 3	4000
76000	2	0.22	152000	0.85	19225	1 1	16000
76000						1 2	4000
80000	4	0.44	320000	1.79	40475	1 1	32000
80000						1 2	8000
84000	4	0.44	336000	1.88	42498	1 1	32000

Robust Q1 numbers set to drive Emami stock

Expectations of revenue growth, margin expansion among triggers

RAM PRASAD SAHU
Mumbai, 5 September

The stock of consumer goods major Emami has corrected nearly 3.5 per cent since its 52-week high of ₹546.25. On Tuesday, the stock closed at ₹521.90 on the BSE.

After underperforming the Nifty FMCG index for a long time, the stock is now doing a catch up and surged over 13 per cent in the past one month. It has been on an uptrend since its March lows, gaining about 54 per cent during this period. This has helped the stock narrow its underperformance vis-a-vis the sector index seen over the past one year.

The recent gains in the stock have been on the back of robust quarter numbers, expectations of revenue growth, margin expansion and reduction in promoter share pledge.

Overall, growth for the company in the June quarter came in at 7 per cent year-on-year (Y-o-Y), and this was broadly in line with estimates.

This is despite sales being dragged down by the sluggish performance of the summer portfolio. Excluding this, domestic business growth was a robust 16 per cent.


The summer portfolio declined by 5 per cent on account of unseasonal rains with the Navratna range witnessing a fall of 8 per cent.

Emami was, however, able to improve sales growth of Dermicool by 9 per cent on the back of distribution initiatives.

Growth in the quarter was led by pain management (up 13 per cent YoY), healthcare (up 11 per cent) and antiseptic cream BoroPlus (up 19 per cent).

On a low base, modern trade and e-commerce channels, which account for about 10 per cent of sales, posted a growth of 45 per cent and 47 per cent, respectively, during the first quarter. Contribution to revenues increased by 510 basis points (bps) Y-o-Y.

The company expects the two channels to grow by 15-20 per cent. For FY24, the company sees a revenue growth of 8-10 per cent with an operating profit margin expansion of 200-250 bps. This



is led by double digit growth in international business, male grooming and healthcare segments. Easing input costs are expected to help boost profitability.

Most brokerages have upgraded their operating profit estimates over the next two-three years due to expectations of a margin recovery.

Analysts led by Percy Panthaki of IIFL Research, said, "With a higher salience of rural and mass-end discretionary products, Emami has been impacted disproportionately in the high inflationary times. Moderation in the overall price index should bode well for demand recovery for Emami."

The brokerage, which has a buy rating, increased its operating profit estimates by 4.7 per cent over FY24-26. This is because it sees a margin recovery.

Nirmal Bang Research, too, has revised its operating profit margin by 7 per cent for FY24 for Emami. This is due to the continued sales momentum and the management guidance of 200-250 bps margin expansion for the ongoing financial year.

Further, the brokerage believes that the stock, which is trading at 21 times its FY25 earnings estimates, is inexpensive. Therefore, it has maintained a 'buy' rating.

Another positive for the stock is the reduction in promoter pledge.

The promoters expect to complete the sale of promoter group hospital (AMRI Hospitals) by the end of this month. They will use part of the proceeds to bring down their share pledge from 33 per cent to 18 per cent.

Multi-asset allocation fund: For diversified, low-volatility portfolio

But steer clear of these if you desire full control over asset allocation

KARTHIK JEROME

There is buzz around the multi-asset allocation (MAA) fund category. Kotak Mutual Fund's new fund offer (NFO) for an MAA Fund is underway and the one by Shriram Asset Management Company has just ended. Bank of India and Quantum's NFOs are in the pipeline. As many as 18 funds in this category manage ₹35,601 crore. These funds garnered only 6.8 per cent average return in 2022 but are up 11.9 per cent year-to-date.

Investment approach

According to the Securities and Exchange Board of India (Sebi), these funds must invest in a minimum of three asset classes, with at least 10 per cent allocation to each. MAA funds generally invest in equities, debt, commodities (gold and silver) and real estate, and sometimes also hold real estate investment trusts (REITs) and infrastructure investment trusts (InvITs).

Most funds invest 10-20 per cent in commodities and allocate the rest of the portfolio to equities and debt. "Each fund house has its own model for allocating to equities and debt, which usually depends on earnings, valuation, and so on," says Alekh Yadav, head of investment products, Sanctum Wealth. Equity

allocation can be as low as 20-30 per cent and go as high as 70-80 per cent. An MAA Fund provides investors with the convenience of a diversified and professionally managed portfolio. "The fund house decides the asset allocation and handles the rebalancing," says Gautam Kalia, senior vice president and head-supervisor, investors, Sharekhan by BNP Paribas.

Investors are saved from potential liabilities and exit load when the fund house carries out the rebalancing.

Yadav says the portfolios of these funds are less volatile and suffer limited drawdowns during market slumps.

One-size-fits-all portfolios

In an MAA Fund, investors delegate con-


EXPECT LONG-TERM RETURNS TO BE IN EARLY TEENS

Category average trailing returns (in %)

YTD	11.9
6-month	13.4
1-year	16.0
2-year	11.2
3-year	18.1
5-year	14.4
7-year	12.5
10-year	13.0

SOUND PERFORMANCE EXCEPT IN 2015 AND 2018

Category average calendar-year returns (in %)



not want. These funds can't offer tailor-made portfolios to each of them.


target investor If you have a moderate risk profile, want a long-term and diversified portfolio, and are comfortable delegating decisions to the fund house, MAA funds are worth considering. "New entrants in equity funds, who are not familiar with the volatility of equities, or non-savvy investors who can't decide their asset allocation, may go for these funds," says Nehal Mota, co-founder, Finnovate.

The funds are also suitable for investors who don't want to manage their portfolios actively, don't want to quit equities entirely, and are looking for capital protection with some amount of growth, she says. Investors who don't have access to a financial advisor or can't make their asset allocation decisions themselves may also opt for these funds.

According to Mota, aggressive investors who want their capital to grow rapidly should avoid these funds.

Understand portfolio composition Don't pick a fund from this category by just comparing rolling returns and risk parameters as one fund may have 70 per cent allocation to equities while another may have only 40 per cent. The two are not directly comparable. "Do an analysis of the fund's portfolio and see if its composition is suited to your risk profile and goal," says Mota.

When a particular asset class, especially equities, does well, these funds will lag behind due to their diversified nature. Avoid quitting this fund in a huff in such an environment.



Continue From Previous Page

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ration of allottees to applicants	Total No. of shares allocated /allotted
84000						3 4	12000
88000	4	0.44	352000	1.97	44522	1 1	32000
88000						3 4	12000
96000	1	0.11	96000	0.53	12142	1 1	12000
100000	1	0.11	100000	0.55	12648	1 1	12000
108000	1	0.11	108000	0.6	13660	1 1	12000
120000	1	0.11	120000	0.67	15178	1 1	16000
124000	1	0.11	124000	0.69	15684	1 1	16000
136000	2	0.22	272000	1.52	34403	1 1	32000
136000						1 2	4000
140000	2	0.22	280000	1.56	35415	1 1	32000
140000						1 2	4000
156000	1	0.11	156000	0.87	19731	1 1	20000
176000	1	0.11	176000	0.98	22261	1 1	24000
180000	1	0.11	180000	1	22767	1 1	24000
200000	1	0.11	200000	1.11	25297	1 1	24000
236000	1	0.11	236000	1.32	29850	1 1	28000
252000	1	0.11	252000	1.41	31874	1 1	32000
268000	1	0.11	268000	1.49	33898	1 1	32000
296000	1	0.11	296000	1.65	37439	1 1	36000
356000	1	0.11	356000	1.99	45028	1 1	44000
540000	2	0.22	1080000	6.04	136602	1 1	136000
712000	1	0.11	712000	3.98	90056	1 1	92000
TOTAL	899	100	17868000	100	2260000		2260000

A. Qualified Institutional Buyers (QIBs)

The Registrar informed that in QIB category, overall 5 valid applications for 54,44,000 Shares were received. QIB Investor have been offered 9.95% of net issue of 50,24,000 shares i.e., 5,00,000 shares. Of these, there were 2 applications for 44,000 Equity Shares bid by non-retail investors in the QIB Category. Accordingly, these 2 applications for 44,000 were re-categorized to non-retail investors Category.

As no application received in the category available for allocation to Mutual Funds only (5% of the QIB portion), so the same will spill over to QIB Investors as applicable:

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ration of allottees to applicants	Total No. of shares allocated /allotted
5,00,000	2	66.66	10,00,000	18.51	92,593	1 1	88,000
5,00,000						1 2	4,000
44,000,000	1	33.33	44,000,000	81.48	4,07,407	1 1	4,08,000
Grand Total	3	100.00	54,000,000	100	5,00,000		5,00,000

Category	FIs/banks	MF's	IC's	NBFC's	AIF	FPI	Others	Total
QIB	4,08,000	-	-	-	-	92,000	-	5,00,000

The Board Meeting of our Company on September 04, 2023 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being NSE and has allotted the Equity Shares to various successful Bidders. The Allotment Advice-cum- refund intimation are being dispatched to the address of the investors as registered with the depositories. Further, the instructions to the Self Certified Syndicate Banks for unlocking of funds, transfer to Public Issue Account have been issued on September 04, 2023 and payment to Non-Syndicate brokers have been issued on September 04, 2023. In case the same is not received within four days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares Allotted to the successful Allottees are being credited to the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from NSE, and the trading is expected to commence on or about September 07, 2023. All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus.

INVESTORS PLEASE NOTE

The details of the Allotment made have been hosted on the website of Registrar to the Issue, BigShare Services Private Limited at www.bigshareonline.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole applicant, Serial number of the ASBA form, number of Equity Shares bid for, name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below:



BIGSHARE SERVICES PRIVATE LIMITED
S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai - 400 093, Maharashtra, India
Telephone: 022 6263 8200
Facsimile: 022 6263 8299
Email: ipo@bigshareonline.com
Investor Grievance Email: investor@bigshareonline.com
Contact Person: Swapnil Kate
Website: www.bigshareonline.com
SEBI Registration Number: INR000001385
CIN: U99999MH1994PTC076534

Date: September 05, 2023
Place: Ahmedabad

For Mono Pharmcare Limited
On Behalf of the Board of Directors
Sd/-
Panilam Lakhatariya
Managing Director

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF MONO PHARMACARE LIMITED

Mono Pharmcare Limited has filed the Prospectus dated September 01, 2023 with Registrar of Companies, Ahmedabad, Gujarat. The Prospectus shall be available on the website of the SEBI at www.sebi.gov.in, the website of the BRLM to the Issue at www.unistonecapital.com and website of NSE at www.nseindia.com. Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled "Risk Factors" beginning on page 28 of the Prospectus.

The Equity Shares offered in the Issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable U.S. state securities laws. There will be no public offering in the United States and the securities being offered in this announcement are not being offered or sold in the United States.

COCHIN INTERNATIONAL AIRPORT LTD.
TENDER NOTICE 06.09.2023
Online E-Tenders are invited from reputed agencies for the Management of LAN at Cochin International Airport Limited.
Interested firms may register themselves on the online E-Tendering portal <https://tenders.kerala.gov.in> and then download the Tender documents. For eligibility criteria and other details, visit our website www.cial.aero
Sd/- MANAGING DIRECTOR

PPGCL
PROPRIETARY POWER GENERATION COMPANY LIMITED
Regd Office: Shalabh Bhawan, B12 & 13, Sector 4, Gurgaon, Haryana, India.
Plant Address: PO- Lohara, Tehsil-Sara, Prayagraj (Allahabad), Uttar Pradesh-211207
Phone: +91-120-6102000/6102009 CIN: U40101UP2007PL0032855
NOTICE INVITING EXPRESSION OF INTEREST
Prayagraj Power Generation Company Limited invites expression of interest (EOI) from eligible vendors for Facility Management Services (Catering, Housekeeping, Cleaning, Food Management for Guest Houses, Field Hotel), Mess & Canteen (of 3650 MW Thermal Power Plant at Prayagraj Power Generation Company Limited, Sara, Dist. Prayagraj), Uttar Pradesh, India.
Details of pre-qualification requirements, bid security, purchasing of tender document etc. may be downloaded using the URL-<https://www.ppgcl.co.in/tenders.php>. Eligible vendors willing to participate may submit their expression of interest along with the tender fee for issue of bid document latest by 12th Sep 2023.

M.P. MADHYA KSHETRA VIDYUT VITARAN CO. LTD.
Molijheel, A. B. Road, Gwalior-474010
Phone: 0751-2448200, Fax: 0751-2448280
No. CGM/GR/11-A/2023-24/91144 Gwalior, Dated: 04.09.2023
NOTICE INVITING E-TENDER (OPEN TENDER)
MPMKVCL invites online bids under "Semi-Turn Key Contract" from eligible bidders for following work:
Name of the Works & Services Contract Estimated cost (₹ required) Tender Document fees EMD (In Rs.) Scheduled Time of Completion
Conversion from HVDS system to LT network of 11KV padav feeder and 11KV MPT feeder under phoolbagh zone under city circle Gwalior 2.04 Cr. Rs. 11800/- 408900/- 90 days
Bid documents shall be on sale from 04.09.2023, 17:30 Hrs Online and shall be received up to 15:00 Hrs of 25.09.2023 and shall be opened on 26.09.2023 and after technical/financial evaluation necessary price Bid will be opened. Relevant details of full tender will be available on our Company website : portal.mpcz.in and on e-portal : <https://mptenders.gov.in> from the dates as mentioned above.
M.P. Madhya/111852/2023 CHIEF GENERAL MANAGER (GR)